Email Alert RSS
Volume 15 Issue 1
Jan.  2024
Turn off MathJax
Article Contents
Abstract
References
Related Articles
QIN Jing, ZHU Qingli. Early Efficacy Assessment of Targeted Therapy for Crohn's Disease by Ultrasound[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(1): 130-134. DOI: 10.12290/xhyxzz.2023-0306
Citation: QIN Jing, ZHU Qingli. Early Efficacy Assessment of Targeted Therapy for Crohn's Disease by Ultrasound[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(1): 130-134. DOI: 10.12290/xhyxzz.2023-0306
shu

Early Efficacy Assessment of Targeted Therapy for Crohn's Disease by Ultrasound

  • 1.

    Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Department of Ultrasound, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

National High-Level Hospital Clinical Research Funding 2022-PUMCH-C-018

National Natural Science Foundation of China 81791640

More Information
  • Corresponding author:

    ZHU Qingli, E-mail: zqlpumch@126.com

  • Received Date: June 26, 2023
  • Accepted Date: July 30, 2023
  • Issue Publish Date: January 29, 2024
    Graphical Abstract
    • Abstract
  • Crohn's disease (CD) is a chronic inflammatory bowel disease with complicated pathogenesis and prolonged condition. In recent years, with the development of targeted therapy, biological agents have been widely used in the treatment of CD, which has significantly improved the prognosis of CD patients. If the efficacy evaluation can be carried out at the early stage of targeted therapy, it may help to figure out the patients who can benefit from the treatment and optimize the treatment plan for the ineffective patients in time. In the evaluation of CD activity and efficacy, ultrasound has the advantages of high accuracy, no radiation and high patient acceptance, and therefore has potential clinical application value in the early efficacy evaluation of CD targeted therapy. This article reviews the research progress to provides a reference for optimizing the treatment plan for CD patients.
    • FullText(HTML)
    • References (22)
  • [1]
    Lichtenstein G R, Loftus E V, Isaacs K L, et al. ACG clinical guideline: management of Crohn's disease in adults[J]. Am J Gastroenterol, 2018, 113(4): 481-517. DOI: 10.1038/ajg.2018.27
    [2]
    Ilvemark J F K F, Hansen T, Goodsall T M, et al. Defining transabdominal intestinal ultrasound treatment response and remission in inflammatory bowel disease: systematic review and expert consensus statement[J]. J Crohns Colitis, 2022, 16(4): 554-580. DOI: 10.1093/ecco-jcc/jjab173
    [3]
    Drews B H, Barth T F E, Hänle M M, et al. Comparison of sonographically measured bowel wall vascularity, histo-logy, and disease activity in Crohn's disease[J]. Eur Radiol, 2009, 19(6): 1379-1386. DOI: 10.1007/s00330-008-1290-5
    [4]
    Novak K L, Nylund K, Maaser C, et al. Expert consensus on optimal acquisition and development of the international bowel ultrasound segmental activity score[IBUS-SAS]: a reliability and inter-rater variability study on intestinal ultrasonography in Crohn's disease[J]. J Crohns Colitis, 2021, 15(4): 609-616. DOI: 10.1093/ecco-jcc/jjaa216
    [5]
    Dragoni G, Gottin M, Innocenti T, et al. Correlation of ultrasound scores with endoscopic activity in Crohn's disease: a prospective exploratory study[J]. J Crohns Colitis, 2023, 17(9): 1387-1394. DOI: 10.1093/ecco-jcc/jjad068
    [6]
    Bots S, Nylund K, Löwenberg M, et al. Ultrasound for assessing disease activity in IBD patients: a systematic review of activity scores[J]. J Crohns Colitis, 2018, 12(8): 920-929. DOI: 10.1093/ecco-jcc/jjy048
    [7]
    Goodsall T M, Nguyen T M, Parker C E, et al. Systematic review: gastrointestinal ultrasound scoring indices for inflammatory bowel disease[J]. J Crohns Colitis, 2021, 15(1): 125-142. DOI: 10.1093/ecco-jcc/jjaa129
    [8]
    Castiglione F, Mainenti P, Testa A, et al. Cross-sectional evaluation of transmural healing in patients with Crohn's disease on maintenance treatment with anti-TNF alpha agents[J]. Dig Liver Dis, 2017, 49(5): 484-489. DOI: 10.1016/j.dld.2017.02.014
    [9]
    Castiglione F, Testa A, Rea M, et al. Transmural healing evaluated by bowel sonography in patients with Crohn's disease on maintenance treatment with biologics[J]. Inflamm Bowel Dis, 2013, 19(9): 1928-1934.
    [10]
    Orlando S, Fraquelli M, Coletta M, et al. Ultrasound elasticity imaging predicts therapeutic outcomes of patients with Crohn's disease treated with anti-tumour necrosis factor antibodies[J]. J Crohns Colitis, 2018, 12(1): 63-70. DOI: 10.1093/ecco-jcc/jjx116
    [11]
    De Voogd F, Bots S, Gecse K, et al. Intestinal ultrasound early on in treatment follow-up predicts endoscopic response to anti-TNFα treatment in Crohn's disease[J]. J Crohns Colitis, 2022, 16(10): 1598-1608. DOI: 10.1093/ecco-jcc/jjac072
    [12]
    Calabrese E, Rispo A, Zorzi F, et al. Ultrasonography tight control and monitoring in Crohn's disease during different biological therapies: a multicenter study[J]. Clin Gastroenterol Hepatol, 2022, 20(4): e711-e722. DOI: 10.1016/j.cgh.2021.03.030
    [13]
    Paredes J M, Moreno N, Latorre P, et al. Clinical impact of sonographic transmural healing after anti-TNF antibody treatment in patients with Crohn's disease[J]. Dig Dis Sci, 2019, 64(9): 2600-2606. DOI: 10.1007/s10620-019-05567-w
    [14]
    Kucharzik T, Wittig B M, Helwig U, et al. Use of intestinal ultrasound to monitor Crohn's disease activity[J]. Clin Gastroenterol Hepatol, 2017, 15(4): 535-542. e2. DOI: 10.1016/j.cgh.2016.10.040
    [15]
    Ripollés T, Paredes J M, Martínez-Pérez M J, et al. Ultrasonographic changes at 12 weeks of anti-TNF drugs predict 1-year sonographic response and clinical outcome in Crohn's disease: a multicenter study[J]. Inflamm Bowel Dis, 2016, 22(10): 2465-2473. DOI: 10.1097/MIB.0000000000000882
    [16]
    Paredes J M, Ripollés T, Cortés X, et al. Abdominal sonographic changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's Disease[J]. Dig Dis Sci, 2010, 55(2): 404-410. DOI: 10.1007/s10620-009-0759-7
    [17]
    Goertz R S, Klett D, Wildner D, et al. Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study[J]. Acta radiol, 2018, 59(10): 1149-1156. DOI: 10.1177/0284185117752032
    [18]
    Quaia E, Sozzi M, Angileri R, et al. Time-intensity curves obtained after microbubble injection can be used to differentiate responders from nonresponders among patients with clinically active Crohn disease after 6 weeks of pharmacologic treatment[J]. Radiology, 2016, 281(2): 606-616. DOI: 10.1148/radiol.2016152461
    [19]
    Quaia E, Gennari A G, Cova M A. Early predictors of the long-term response to therapy in patients with Crohn disease derived from a time-intensity curve analysis after microbub-ble contrast agent injection[J]. J Ultrasound Med, 2019, 38(4): 947-958. DOI: 10.1002/jum.14778
    [20]
    Saevik F, Nylund K, Hausken T, et al. Bowel perfusion measured with dynamic contrast-enhanced ultrasound predicts treatment outcome in patients with Crohn's disease[J]. Inflamm Bowel Dis, 2014, 20(11): 2029-2037. DOI: 10.1097/MIB.0000000000000159
    [21]
    Baumgart D C, Müller H P, Grittner U, et al. US-based real-time elastography for the detection of fibrotic gut tissue in patients with stricturing Crohn disease[J]. Radiology, 2015, 275(3): 889-899.
    [22]
    Chen Y J, Chen B L, Liang M J, et al. Longitudinal bowel behavior assessed by bowel ultrasound to predict early response to anti-TNF therapy in patients with Crohn's disease: a pilot study[J]. Inflamm Bowel Dis, 2022, 28(Suppl 2): S67-S75.
    • Related Articles

  • Related Articles

    [1]WANG Qi, CHEN Miao. Advances in Immunotargeted Therapy for Warm Autoimmune Hemolytic Anemia[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 423-430. DOI: 10.12290/xhyxzz.2024-0668
    [2]WANG Jun, MENG Juan. Targeted Therapy for Rheumatoid Arthritis in the New Era[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 19-27. DOI: 10.12290/xhyxzz.2024-0842
    [3]LIN Meijia, ZENG Yeting, WANG Xinrui, HUANG Xiongfei. Research Progress of Isocitrate Dehydrogenase Gene Mutation Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 346-352. DOI: 10.12290/xhyxzz.2022-0176
    [4]SHEN Tian, WU Xiaochuan. Systemic Lupus Erythematosus: from Pathogenesis to New Targeted Therapies[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 234-240. DOI: 10.12290/xhyxzz.2022-0694
    [5]LI Guo-yu, HE Ming. Research Progress of Targeted Therapy at Rare Targets for Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 268-274. DOI: 10.3969/j.issn.1674-9081.2020.00.019
    [6]CHEN Bo, YANG Hui-xiang. The Role of Visceral Adipose Tissue in the Pathogenesis, Diagnosis, and Treatment of Crohn's Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 73-79. DOI: 10.3969/j.issn.1674-9081.2020.00.007
    [7]Ying XU, Yan LIN, Chang-jun WANG, Jia-lin ZHAO, Qiang SUN. Whether Elderly Patients with Her-2 Positive Breast Cancer but Without Heart Disease Should Receive Targeted Therapy?[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(4): 414-418. DOI: 10.3969/j.issn.1674-9081.2019.04.020
    [8]Su-jie ZHANG, Hua-qi YIN, Xiong-jun YE, Tao XU. Role of Musashi-2 in the Occurrence and Development and as the Diagnostic and Therapeutic Target of Malignant Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 289-293. DOI: 10.3969/j.issn.1674-9081.2017.05.018
    [9]Qian CAO. The Crucial Problems in the Treatment of Crohn's Disease with Anti-tumor Necrosis Factor-α Monoclonal Antibody[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 207-209. DOI: 10.3969/j.issn.1674-9081.2017.05.003
    [10]Lei TANG, Hua-dan XUE, Zheng-yu JIN. Radiological Evaluation of the Response of Abdominal Tumors to Targeted Therapy: Current Status and Prospect[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 82-89. DOI: 10.3969/j.issn.1674-9081.2017.03.001

  • Cited by

    Periodical cited type(7)

    1. 杨利伟. 同意原则的伦理向度:从生命伦理到多元实践. 道德与文明. 2025(01): 145-156 .
    2. 夏振兰，刘俊荣，刘泽炫，陈丽萍. 慢性伤口处理中的临床伦理困境探析——以1例产后脂肪液化合并线结反应的慢性伤口患者护理为例. 中国医学伦理学. 2024(02): 194-198 .
    3. 朱敏，陈昌林，李明. 老年患者麻醉知情同意的临床伦理分析. 中国当代医药. 2024(14): 124-128 .
    4. 王茜，夏曼. 知情同意权的伦理应用困境与对策. 江苏卫生事业管理. 2024(11): 1559-1562 .
    5. 陶应时，陈巧，刘红玉. 治疗型脑机接口的知情同意问题及其应对. 南华大学学报(社会科学版). 2023(01): 62-68 .
    6. 夏振兰，陈丽萍，杨林玲，廖绮霞，刘俊荣. 一例慢性伤口不愈合患者拒绝住院治疗的伦理剖析. 中国医学伦理学. 2022(09): 1012-1016 .
    7. 张曼. 脑隐私法律概念建构：路径、特性与贡献. 东方法学. 2022(05): 60-73 .

    Other cited types(4)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (290) PDF downloads (55) Cited by(11)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close